Table 1.
Characteristics of the unilateral breast cancer cohort and the CBC-cohort; 1976–2005 in the Stockholm-Gotland region.
Figure 1.
Cumulative incidence of CBC for women with ER-negative vs. ER-positive first breast cancer. Panel A shows the cumulative incidence of CBC of any ER-subtype by ER-status of the first cancer. The p-value for the log-rank test of cumulative incidence of CBC overall was 0.338, thus the cumulative incidence of CBC did not differ between patients with ER-positive vs. ER-negative first primary breast cancer. Panel B shows the cumulative incidence of ER-positive and ER-negative CBC by ER-status of the first cancer. (The p-value for the log-rank test of cumulative incidence of ER-positive CBC show significant difference between patients with ER-positive vs. ER-negative first breast cancer (P-value = <0.001) and similarly the p-value for the log-rank test of cumulative incidence of ER-negative CBC also show significant difference between patients with ER-positive vs. ER-negative first breast cancer (P-value = <0.001). See Table 5 for number of women at risk.
Table 2.
Standardized incidence ratios (SIR) comparing the incidence of CBC to the incidence of unilateral breast cancer, overall and according to ER-status of the first breast cancer, for all patients and stratified on age.
Table 3.
Standardized incidence ratios (SIR) comparing the incidence of ER-positive and ER-negative CBC to the incidence of unilateral breast cancer, overall and according to ER-status of the first breast cancer, for all patients and stratified on age.
Table 4.
Standardized incidence ratios (SIR) comparing the incidence of CBC to the incidence of unilateral breast cancer, for CBC overall and for specific ER-status of first and second breast cancer, taking hormone therapy for the first cancer into account.
Table 5.
Number of women at risk of CBC by year after diagnosis, subdivided on ER-status of the first cancer.